Ocuphire Pharma, Inc.
NASDAQ:OCUP
1.17 (USD) • At close October 23, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2009 | 2008 | 2007 | 2006 | 2005 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 19.049 | 39.85 | 0.589 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.191 |
| Cost of Revenue
| 0.006 | 0.004 | 0.004 | 0.008 | 0.003 | 0.048 | 0.042 | 0.033 | 0.027 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 19.043 | 39.846 | 0.585 | -0.008 | -0.003 | -0.048 | -0.042 | -0.033 | -0.027 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.191 |
| Gross Profit Ratio
| 1 | 1 | 0.993 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Reseach & Development Expenses
| 17.653 | 14.355 | 15.173 | 6.648 | 2.373 | 13.109 | 10.715 | 10.089 | 12.148 | 7.016 | 3.253 | 3.393 | 11.992 | 3.252 | 2.43 | 1.527 | 3.325 | 1.524 |
| General & Administrative Expenses
| 11.959 | 7.269 | 8.121 | 2.818 | 1.82 | 0.743 | 6.639 | 6.324 | 6.115 | 6.253 | 4.26 | 2.713 | 3.548 | 2.944 | 2.526 | 2.728 | 3.051 | 2.557 |
| Selling & Marketing Expenses
| -0.006 | 0 | 0 | 0 | 0 | 6.637 | -0.042 | -0.033 | -0.027 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 11.953 | 7.269 | 8.121 | 2.818 | 1.82 | 7.38 | 6.597 | 6.291 | 6.088 | 6.253 | 4.26 | 2.713 | 3.548 | 2.944 | 2.526 | 2.728 | 3.051 | 2.557 |
| Other Expenses
| 1.837 | -0.014 | -0.157 | 0.009 | -0.068 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 29.606 | 21.624 | 23.294 | 9.466 | 4.193 | 20.489 | 17.312 | 16.38 | 18.236 | 13.269 | 7.514 | 6.106 | 15.54 | 6.196 | 4.955 | 4.255 | 6.377 | 4.082 |
| Operating Income
| -10.563 | 18.226 | -22.705 | -19.968 | -4.193 | -20.538 | -17.355 | -16.413 | -18.263 | -13.269 | -7.979 | -6.58 | -16.131 | -6.466 | -5.152 | -4.432 | -6.718 | 0 |
| Operating Income Ratio
| -0.555 | 0.457 | -38.548 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 0.589 | -0.023 | -33.988 | -4.652 | -1.976 | 6.169 | -7.94 | 7.106 | 3.879 | -5.252 | -1.521 | 0.353 | 4.786 | 0.078 | 0.24 | 0.128 | 0.232 | -1.631 |
| Income Before Tax
| -9.974 | 18.203 | -56.693 | -24.62 | -6.169 | -14.369 | -25.295 | -9.307 | -14.385 | -18.522 | -9.499 | -6.227 | -11.345 | -6.387 | -4.912 | -4.304 | -6.486 | -6.35 |
| Income Before Tax Ratio
| -0.524 | 0.457 | -96.253 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -33.312 |
| Income Tax Expense
| 0.012 | 0.315 | -0.159 | 6.856 | 1.341 | -0.161 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6.35 |
| Net Income
| -9.986 | 17.888 | -56.534 | -31.476 | -7.51 | -14.369 | -25.295 | -9.307 | -14.385 | -18.522 | -9.499 | -6.227 | -11.345 | -6.387 | -4.912 | -4.304 | -6.486 | -6.35 |
| Net Income Ratio
| -0.524 | 0.449 | -95.983 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -33.312 |
| EPS
| -0.46 | 0.9 | -3.81 | -6.75 | -10.56 | -20.95 | -44.33 | -20.55 | -37.86 | -0.11 | -0.074 | -0.064 | -0.12 | -0.1 | -0.088 | -0.086 | -0.13 | -0.15 |
| EPS Diluted
| -0.46 | 0.87 | -3.81 | -6.75 | -10.56 | -20.95 | -44.33 | -20.55 | -37.86 | -0.11 | -0.074 | -0.064 | -0.12 | -0.1 | -0.088 | -0.086 | -0.13 | -0.15 |
| EBITDA
| -9.968 | 18.23 | -56.687 | -19.968 | -4.19 | -14.32 | -25.252 | -8.961 | -14.357 | -13.269 | -7.942 | -6.537 | -16.086 | -6.424 | -5.097 | -4.239 | -6.593 | -6.056 |
| EBITDA Ratio
| -0.554 | 0.457 | -38.815 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.506 |